Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models

Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models

Background Epidermal growth factor receptor (EGFR)-targeted agents have demonstrated clinical benefit in patients with cancer. Identifying tissue-of-origin-independent predictive biomarkers is important to optimally treat patients. We sought to identify a gene array profile that could predict respo...

Full description

Bibliographic Details
Main Authors:	Michael J. Boedigheimer, Daniel J. Freeman, Panteha Kiaei, Michael A. Damore, Robert Radinsky
Format:	Article
Language:	English
Published:	Elsevier 2013-02-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558613800231

Similar Items

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab
by: Hiroya Taniguchi, et al.
Published: (2018-07-01)

Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma – A Report of Two Cases
by: G. Ramadori, et al.
Published: (2010-05-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
by: Freeman Daniel J, et al.
Published: (2012-07-01)

Prospective noninterventional study on the use of panitumumab monotherapy in patients with recurrent or progressive colorectal cancer: the VECTIS study
by: Lakomy R, et al.
Published: (2015-10-01)

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer
by: James M. Lindberg, et al.
Published: (2014-07-01)

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021-08-01)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
by: Ho Wai Derrick Siu, et al.
Published: (2021-08-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
by: Tapan K Nayak, et al.
Published: (2011-03-01)

Metastatic colorectal cancer: treatment with panitumumab
by: Antonio Silvinato, et al.

Treatment of metastatic colorectal cancer: focus on panitumumab
by: Tay RY, et al.
Published: (2015-06-01)

Hormone Profiles with Valproate Monotherapy
by: J Gordon Millichap
Published: (2001-09-01)

Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer
by: Patel SB, et al.
Published: (2015-12-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-02-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-01-01)

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
by: Jingquan Jia, et al.
Published: (2018-08-01)

Patient considerations in metastatic colorectal cancer – role of panitumumab
by: Rogers JE
Published: (2017-04-01)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
by: E Allen Sickmier, et al.
Published: (2016-01-01)

Monotherapy with Anti-LFA-1 Monoclonal Antibody Promotes Long-Term Survival of Rat Islet Xenografts
by: Eric B. Tredget, et al.
Published: (2008-06-01)

RESULTS OF PANITUMUMAB ADDITION TO CONVERSION THERAPY FOR COLORECTAL CANCER LIVER METASTASES
by: M. I. Sekacheva, et al.
Published: (2015-02-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
by: Adriana Camargo Carvalho, et al.
Published: (2017-01-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma
by: Paulo Ricardo Saquete Martins-Filho, et al.
Published: (2013-01-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
by: Kerry J Williams, et al.
Published: (2009-06-01)

Cultured circulating tumor cells and their derived xenografts for personalized oncology
by: Ruoxiang Wang, et al.
Published: (2016-10-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

Applications of patient-derived tumor xenograft models and tumor organoids
by: Go J. Yoshida
Published: (2020-01-01)

Gamma Knife Surgery as Monotherapy with Clinically Relevant Doses Prolongs Survival in a Human GBM Xenograft Model
by: Bente Sandvei Skeie, et al.
Published: (2013-01-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
by: Hendrikx JJMA, et al.
Published: (2020-10-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
by: Mareike Voigt, et al.
Published: (2012-11-01)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
by: Howard Burris, et al.
Published: (2011-01-01)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer
by: Giampietro Gasparini, et al.
Published: (2014-09-01)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
by: George P Kim, et al.
Published: (2008-06-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach
by: Ilaria Piga, et al.
Published: (2020-08-01)

Transcriptional Profiling of Porcine HCC Xenografts Provides Insights Into Tumor Cell Microenvironment Signaling
by: Shovik S. Patel, et al.
Published: (2021-04-01)